Figure 1.
Biodemographic and tumor characteristics of the study population
| Median Age years (range) | 12 (4 –37) |
| Pediatric (below 18 years) | 76 (67.3%) |
| Adult (above 18 years) | 37 (32.7%) |
| Male: Female | 70:43 |
| Risk Stratification | |
| High Risk | 78 (69.4%) |
| Standard Risk | 35 (30.6%) |
| Extent of surgery | |
| GTR/NTR | 43 (38.1%) |
| STR | 70 (61.9%) |
| CSF | |
| positive | 16 (14.2%) |
| negative | 97 (85.8%) |
| Time between surgery and RT | |
| <6 weeks | 69 (61.1%) |
| >6 weeks | 44 (38.9%) |
| Concurrent chemotherapy | |
| yes | 76 (67.3%) |
| no | 37 (32.7%) |
| Toxicity (Grade 2 and Above) | |
| Bone Marrow Suppression | 13 (11.5%) |
| Esophagitis | 12 (10.6%) |
| Nausea/vomiting | 12 (10.6%) |
| Weight loss | 10 (8.8%) |
| Diarrhea | 5 (4.4%) |
| Vision changes | 2 (1.8%) |
Dosimetric characteristics of the study population
| CSI dose (Gy) | 23.4/36 |
| Boost spine (Gy) | 14.4–30.6 |
| Boost to primary (Gy) | 54–55.4 |
| Mean PTV coverage | 96% +/− 1.23 |
| PTV D99 | 93.8% +/− 2.34 |
| PTV D1 | 106% +/− 1.45 |
| Number of isocenters | |
| 2 | 11 (9.7%) |
| >2 | 102 (90.3%) |
| Conformity index (CI) | 1.02(0.98–1.08) |
| Homogeneity index (HI) | 0.1 (0.14–0.09) |
| Mean Length (PTV) | 62.4 +/− 9.78 |
| Median ARC | 5 (3–7) |
| Left Kidney Mean | 6.5Gy +/− 2.32 |
| Right Kidney Mean | 6.5Gy +/− 2.32 |
| V19 Liver mean | 0.47cc +/− 1.02 |
| Heart Mean | 6.5Gy +/−2.61 |
| Bowel Mean | 6.1Gy +/− 3.56 |
| Lung mean | 7.2Gy +/− 1.83 |
| Setup Position | |
| Prone | 24 (21.2%) |
| Supine | 89 (78.7%) |
| Median ARC | 5 (3–7) |